Login to Your Account



Alzheimer's strikes again as Axovant slumps on MINDSET failure

By Marie Powers
News Editor

Tuesday, September 26, 2017

Despite big boasts about the novelty of its 5-HT6 pathway approach to treat Alzheimer's disease, Axovant Sciences Ltd. found its phase III effort just as wanting as those of every other biopharma that's sought in recent years to tame the deadly neurodegenerative disease.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription